Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2946707 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2BRD4ALOX5ALOX5APGSK3B | |
| SCHEMBL11994492 | 0.86 | ALOX5 (0.48) | SMN1; SMN2BRD4ALOX5ALOX5APGSK3B | |
| SCHEMBL2940825 | 0.86 | SMN1; SMN2 (0.48) | SMN1; SMN2BRD4ALOX5ALOX5APGSK3B | |
| SCHEMBL2940893 | 0.84 | HDAC8 (0.47) | SMN1; SMN2BRD4ALOX5ALOX5APGSK3B | |
| SCHEMBL2940892 | 0.84 | HDAC8 (0.47) | SMN1; SMN2BRD4ALOX5ALOX5APGSK3B | |
| SCHEMBL2939968 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2BRD4ALOX5ALOX5APGSK3B | |
| SCHEMBL12939004 | 0.82 | ALOX5 (0.46) | SMN1; SMN2BRD4ALOX5ALOX5APGSK3B | |
| SCHEMBL12939000 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2BRD4ALOX5ALOX5APGSK3B | |
| SCHEMBL2948361 | 0.81 | CSNK2A2 (0.46) | SMN1; SMN2ALOX5ALOX5APMAPTCSNK2A2 | |
| SCHEMBL2948691 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2BRD4ALOX5ALOX5APMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | disclosed |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-11-16 | — | — | US | disclosed |
| US-9718793-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (R&D) LTD. (GB) | 2017-08-01 | — | — | US | disclosed |
| US-20130289026-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| US-8507480-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (R&D) LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-8450310-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (R&D) LIMITED (GB) | 2013-05-28 | — | — | US | disclosed |
| US-20120252797-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| EP-1611112-B1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | VERNALIS CAMBRIDGE LTD (GB) | 2012-08-22 | — | — | EP | disclosed |
| US-20100179138-A1 | Isozazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| US-7705027-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252797-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | HSP90AB1, HSP90AB2P, HSP90AA1 | SMN1; SMN2 4020/4885BRD4 1328/4885ALOX5 3662/4885 |
| US-20100179138-A1 | Isozazole Compounds As Inhibitors Of Heat Shock Proteins | HSP90AB1, HSP90AA1, HSP90AB2P | SMN1; SMN2 3230/4885BRD4 2216/4885ALOX5 3167/4885 |
| US-20130289026-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | HSP90AB1, HSP90AA1, HSP90AB2P | SMN1; SMN2 2928/4885BRD4 2407/4885ALOX5 2909/4885 |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | HSP90AB1, HSP90AA1, HSP90AB2P | SMN1; SMN2 2928/4885BRD4 2407/4885ALOX5 2909/4885 |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | SMN1; SMN2 2977/4885BRD4 2126/4885ALOX5 3173/4885 |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | SMN1; SMN2 2968/4885BRD4 2399/4885ALOX5 2892/4885 |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | SMN1; SMN2 2928/4885BRD4 2407/4885ALOX5 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.